This book examines the regulatory framework for untested and unapproved (off-label) uses of medicines in the EU, UK and USA. While off-label uses may offer hope, they may also expose patients to risks and uncertainties. This work clarifies the regulatory mechanisms and litigation trends concerning off-licence prescriptions in these jurisdictions.